 ROCKVILLE, Md. and EMERYVILLE, Calif., Oct. 11, 2021 GLOBE NEWSWIRE -- Supernus Pharmaceuticals, Inc. Nasdaq: SUPN and Adamas Pharmaceuticals, Inc. Nasdaq: ADMS, today announced a definitive agreement for Supernus to acquire Adamas through a tender offer for 8.10 per share in cash or an aggregate of approximately 400 million, payable at closing plus two non-tradable contingent value rights CVR collectively worth up to 1.00 per share in cash or an aggregate of approximately 50 million, for a total consideration of 9.10 per share in cash or an aggregate of approximately 450 million. The first CVR, worth 0.50 per share, is payable upon achieving net sales of GOCOVRI of 150 million in any four consecutive quarters between closing and the end of 2024. The second CVR, worth 0.50 per share, is payable upon achieving net sales of GOCOVRI of 225 million in any four consecutive quarters between closing and the end of 2025. The transaction is expected to close in late fourth quarter 2021 or in early first quarter 2022. 